In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Editas Medicine Inc (EDIT). The company’s shares closed yesterday at $24.63.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 2.9% and a 45.7% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Editas Medicine Inc with a $46.33 average price target, representing an 88.1% upside. In a report issued on July 23, Raymond James also maintained a Buy rating on the stock with a $44 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $33.80 and a one-year low of $17.80. Currently, Editas Medicine Inc has an average volume of 688.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9).
